Dementia with Lewy bodies and reduced dopamine transporter binding indicates significant cholinergic deficit: Therapeutic implications of abnormal dopamine transporter imaging with I123-labelled loflupane (DaTSCAN™);Demenz mit Lewy-körperchen und verminderter dopamin-transporter- bindung verweist auf acetylcholin-mangel therapeutische implikationen des DaTSCAN™

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 18 SUPPL. 1, 2008, Pages

  Forstl H ^a   Gratz, S ^b   Hahn, U ^b   Schwarz, J ^c   Jarnig, M ^d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Stuttgart Bad Cannstatt ^*

^c UNIVERSITY OF LEIPZIG   (Germany)

^d GE HEALTHCARE   (Germany)

Author keywords

Acetylcholine; Cholinesterase inhibitor; Cholinopathy; DaT; Dementia; Lewy bodies

Indexed keywords

CHOLINESTERASE INHIBITOR; DOPAMINE TRANSPORTER; IODINE 123; IOFLUPANE; RADIOPHARMACEUTICAL AGENT; ACETYLCHOLINE;

ALZHEIMER DISEASE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC TRANSMISSION; HUMAN; LEWY BODY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; CHEMISTRY; CORPUS STRIATUM; DIFFUSE LEWY BODY DISEASE; METABOLISM; METHODOLOGY; PATHOLOGY; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA;

ACETYLCHOLINE; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; LEWY BODIES; LEWY BODY DISEASE; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SUBSTANTIA NIGRA;

EID: 44949201752     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1075680     Document Type: Review

References (26)

1. Boecker H, Ceballos-Baumann AO, Volk D et al. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol 2007; 64: 984-988
2. Braak H, del Tredici K, Rüb U et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211
3. Edwards K, Royall D, Hershey L et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dementia Geriat Cog Disord 2007; 23: 401-405
4. Egert S, Wagenpfeil S, Förstl H. Cholinesterase-Inhibitoren und Alzheimer Demenz: Meta-Analyse und Wirksamkeitsnachweis, Ursprung und Ergebnisverzerrung in publizierten Studien. Dtsch Med Wochenschr 2007; 132: 1207-1213
5. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229-237
6. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. New Engl J Med 2004; 351: 2509-2518
7. Förstl H, Bickel H, Frölich L et al. MCI-plus: leichte cognitive Beeinträchtigung mit Vorzeichen rascher Verschlechterung. Dtsch Med Wochenschr 2008; 133: 431-436
8. Förstl H, Burns A, Levy R et al. Neuropathological correlates of psychotic phenomena in confirmed Alzheimers-disease. Brit J Psychiat 1994; 165: 53-59
9. Förstl H, Burns A, Luthert P et al. The Lewy-Body variant of Alzheimers-disease clinical and pathological findings. Brit J Psychiat 1993; 162: 385-392
10. Förstl H, Maelicke A, Weichel C. Demenz - Taschenatlas spezial. Stuttgart: Thieme, 2005
11. Grimmer T, Diehl J, Drzezga A et al. Region-specific decline of cerebral glucose metabolism in patients with frontotemporal dementia: a prospective F-18-FDG-PET study. Dementia Geriat Cog Disord 2006; 18: 32-36
12. Hentschel F, Braus DF, Zerfass R et al. Kortikobasale Degeneration in CT und MRI. Fortschr Röntgenstrahlen Neu Bildg Verfahren 1995; 163: 88-90
13. Joseph KA, Whitwell JL, Boeve B et al. Visual hallucinations in posterior cortical atrophy. Arch Neurol 2006; 63: 1427-1432
14. Kurlan R, Cummings L, Raman R et al. Quetiapine for agitation or psychosis in patients with dementia and Parkinsonism. Neurology 2007; 68: 1356-1363
15. Litvan I, Bhatia K, Burn DJ et al. SIC Task Force Appraisal of Clinical Diagnostic Criteria for Parkinsonian Disorders. Mov Disord 2003; 18: 467-486
16. McKeith IG, del Ser T, Spano P et al., Efficacy of rivastigmine in dementia with Lewy-bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2004; 356: 2031-2036
17. McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology 2005; 65: 1863-1872
18. McKeith IG, O'Brien J, Walker Z et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multi-centre study. Lancet Neurol 2007; 6: 305-313
19. McKeith IG, Wesnes KA, Perry E et al. Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy-bodies. Dementia Geriatr Cog Disord 2004; 18: 94-100
20. MRC-CFAS. Pathological correlates of late-onset dementia in a multicentre community-based population in England and Wales. Lancet 2001; 357: 169-175
21. Müller T, Welnic J, Fuchs G et al. The DONPAD-study - treatment of dementia in patients with Parkinson's disease with donepezil. J Neural Transmission 2006; 71, Suppl: 27-30
22. Perneczky R, Mösch D, Neumann M et al. The Alzheimer variant of Lewy body disease: A pathologically confirmed case-control study. Dement Geriat Cog Dis 2005; 20: 89-94
23. Ransmayr G, Katzenschlager R, Dal-Bianco P et al. Lewy-Körper-Demenz und ihre differentialdiagnostische Abgrenzung von Alzheimerscher Erkrankung. Neuropsychiatrie 2007; 21: 63-74
24. Riedel O, Dodel R, Spottke A et al. Wie beurteilen Ärzte die Häufigkeit dementieller, depressiver und psychotischer Symptome bei Patienten mit Parkinson Krankheit? Akt Neurol 2006; 33: 374-380
25. Tiraboschi P, Hansen LA, Alford M et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiat 2002; 59: 946-51
26. Walker Z, Costa DC, Walker RW et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002; 73: 134-140